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OBJECTIVES: The aim of the current study was to compare the objective and subjective effects of continuous positive
airway pressure to the use of nasal dilator strips in patients with acromegaly and moderate to severe obstructive
sleep apnea.
METHODS: We studied 12 patients with acromegaly and moderate to severe obstructive sleep apnea (male/
females = 8/4, age = 52¡8 ys, body mass index = 33.5¡4.6 Kg/m2, apnea–hypopnea index = 38¡14 events/h) who
had been included in a randomized, crossover study to receive three months of treatment with continuous positive
airway pressure and nasal dilator strips. All patients were evaluated at study entry and at the end of each treatment
by polysomnography, and Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index and treatment satisfaction
questionnaires. ClinicalTrials.gov: NCT01265121
RESULTS: The apnea–hypopnea index values decreased significantly with continuous positive airway pressure
treatment but did not change with the use of nasal dilator strips. All of the subjective symptoms improved with both
treatments, but these improvements were significantly greater with continuous positive airway pressure than with
the nasal dilator strips.
CONCLUSION: The use of nasal dilator strips had a much smaller effect on the severity of obstructive sleep apnea in
patients with acromegaly and moderate to severe obstructive sleep apnea in comparison to the use of continuous
positive airway pressure. Moreover, the improvement in several subjective parameters without any significant
objective improvement in obstructive sleep apnea resulting from the use of nasal dilator strips is compatible with a
placebo effect.
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INTRODUCTION
Obstructive sleep apnea (OSA) is a disease characterized
by repeated episodes of complete (apneas) or partial
(hypopneas) cessations of breathing during sleep, which
lead to intermittent hypoxia and disrupted sleep (1). OSA is
common among the general population and is associated
with multiple health problems. Continuous positive airway
pressure (CPAP) is the treatment of the choice for patients
with moderate to severe OSA (2). CPAP can improve sleep
architecture, reduce daytime sleepiness, improve mood, and
reduce automobile accidents (3). There is growing evidence
that the treatment of OSA with CPAP can also improve
several cardiovascular and metabolic outcomes, and this
treatment has been associated with a decrease in deaths due
to cardiovascular issues (4). Data from observational studies
highlight the necessity of randomized controlled trials
(RCTs) to evaluate the effects of CPAP in patients with
OSA in regards to several outcome measurements.
Numerous RCTs have compared the effectiveness of
CPAP to that offered by various control therapies, including
conventional care (5), placebo tablets (6), nasal dilator strips
(NDSs) (7), and sham CPAP (8). Several authors have
argued that shamCPAP should be the placebo intervention of
choice in RCTs. Sham CPAP consists of a CPAP machine that
is modified to contain a large hidden leak in the exhaust port
of themask to disperse the therapeutic pressure, resulting in a
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pressure level at themask interface of generally less than 2 cm
H2O (9). However, the placebo effects of sham CPAP may be
partially hampered by the discomfort and frustration caused
by the necessity of wearing a mask every night with delivery
of suboptimal pressure support (10). The Apnea Positive
Pressure Long-Term Efficacy Study (APPLES) (11) rando-
mized participants to receive six months of active or sham
CPAP, and the results found that not only was adherence to
sham CPAP significantly lower than the adherence to active
CPAP (3.4 vs. 4.2 hours) but that overall study retention was
lower in the sham group compared to the active CPAP group
(S Quan, personal communication). These results suggest that
sham CPAP may not only adversely influence sleep–related
outcomes but may also adversely influence the integrity of
a given study. Despite the need to understand the merits
and limitations of using alternative control interventions
in trials of CPAP, there has been a lack of research specifically
focused on the impact of alternative control interventions
on participant adherence, sleep quality, and other study
outcomes.
NDSs have been designed to mechanically pull the lateral
walls of the nasal vestibule outwards, which dilates the
valve area of the nasal cavity and renders the vestibular wall
stable and resistant to collapse. The strip is placed superior
to the alar cartilage on either side of the nose, which enables
the built–in elastic splints to pull the wall of the vestibule
laterally and dilate the valve area (12). Similar to CPAP,
NDSs are mechanical devices that can be prescribed for
nightly use. However, the two types of devices look and feel
much different, and NDSs are typically less intrusive than
CPAP masks. Because NDSs are widely advocated for the
prevention of snoring and the promotion of nasal breathing
during exercise (13), they may serve as a potential control
intervention for controlled trials evaluating CPAP.
However, it is unclear the extent to which NDSs may
influence study outcomes due to an active rather than a
placebo effect, which would therefore attenuate the esti-
mates of intervention effects associated with the use of
CPAP. In this study, we tested the effects of NDSs in a
particular group of patients with acromegaly and OSA, and
we herein report the effects of a randomized crossover trial
in which the objective and subjective effects of NDSs were
compared to the effects of CPAP in patients with acrome-
galy and moderate to severe OSA.
METHODS
Subjects
We studied patients with acromegaly and OSA who had
been recruited from out–patient clinics at the Division of
Endocrinology and Metabolism of Clinics Hospital, Faculty
of Medicine, University of Sa˜o Paulo. The inclusion criteria
consisted of men and women with acromegaly who were
between 18–70 years of age, had experienced moderate or
severe OSA ($15 events of apnea and hypopnea per hour of
sleep) as documented by polysomnography and who were
naive to treatment. The exclusion criteria included the
following: the presence of kidney or liver disease; malig-
nancy; hypercortisolism; endocrinological diseases, such as
hypothyroidism; uncontrolled diabetes mellitus (glycated
hemoglobin greater than 9%); and a history of alcohol abuse,
angina, acute myocardial infarction, or stroke. The study
was approved by the local institutional review board, and
all patients provided written informed consent.
Sleep Study
Overnight polysomnography was performed in the sleep
laboratory (EMBLA; Flagra hf. Medical Devices, Reykjavik,
Iceland) and included electroencephalography, electroocu-
lography, electromyography, oximetry, measurements of
airflow (oronasal thermistor and pressure cannula), and
measurements of the rib cage and abdominal movements
during breathing. Apnea was defined as the complete
cessation of airflow for at least 10 seconds and associated
with an oxygen desaturation of 3%. Hypopnea was defined
as a significant reduction (.50%) in respiratory signals for
at least 10 seconds and associated with an oxygen
desaturation of 3%. The apnea–hypopnea index (AHI) value
was calculated as the total number of respiratory events
(apneas plus hypopneas) per hours of sleep (14).
Study Design
Following the diagnostic polysomnography confirmation
of moderate to severe OSA, the patients were randomly
assigned, according to a computer-generated list of random
numbers to three months of treatment with NDSs
(ClearPassageH A.K.C, Inc., Korea) or CPAP (REMStar Pro
with C-Flex with humidifier; Respironics, Inc., Murrysville,
PA). After three months, the treatment was discontinued for
one week and then patients were crossed over to the
alternative treatment. At the initiation of each treatment
period, participants underwent full polysomnography to
assess the effects of NDSs or CPAP. Therefore, all patients
underwent a total of three polysomnographic studies
including a diagnostic study, one using CPAP and other
using NDSs. During each three month intervention period,
participants were instructed to use NDSs or CPAP every
night. In each treatment period, participants returned for
evaluation once a week in the first month, and once a month
in the second and third month. CPAP compliance was
objectively measured by data collected on an adherence-
monitoring card (Smart Card; Respironics, Inc.). Similar to a
pill count approach, patients were given a limited number
of NDSs, and adherence was measured by counting the
NDSs that were returned at the next visit. After the
conclusion of the study, CPAP was offered to all of the
patients.
Evaluations
At the time of study entry and after the three-month
intervention, the subjects were weighed and evaluated
according to the questionnaires described below.
Epworth Sleepiness Scale
The Epworth Sleepiness Scale (ESS) was used to evaluate
subjective excessive daytime sleepiness. Briefly, the patient
rated the probability of dozing (from 0 to 3) in eight
different situations, where a score above 10 points repre-
sented the presence of excessive daytime sleepiness (15).
Pittsburgh Sleep Quality Index
Subjective sleep quality was measured according to the
Pittsburgh Sleep Quality Index (PSQI) (16), which is a self–
report questionnaire that assesses sleep quality and dis-
turbances over a one–month interval. The 19– item index
generates the following seven component scores: subjective
sleep quality, sleep latency, sleep duration, habitual efficient
sleep, sleep disturbances, the use of sleeping medications,
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and daytime dysfunction. Each component score is equally
weighed on a 0–3 scale. The sum of these seven component
scores yields a global score ranging from 0 to 21. This
questionnaire has been previously translated and validated
in Brazilian Portuguese (17). Higher global scores indicate
worse sleep quality. A cutoff score of 5 yielded a diagnostic
sensitivity of 89.6% and a specificity of 86.5% for distin-
guishing between good and poor sleepers.
Treatment Satisfaction
A questionnaire was designed to evaluate the level of
satisfaction with the given treatment and included questions
regarding the impact of the treatment on sleep quality,
feelings upon waking, difficulty falling asleep, and satisfac-
tion with the treatment effect concerning daytime sleepi-
ness. The patients were also asked to rate the treatment with
a score from 0–10 (0 =poor, 10 = excellent).
At the end of the study, when the patients had been
exposed to both treatments, they were again asked to rate
each treatment. In addition, participants were asked to list
the advantages and disadvantages of each treatment and
were asked to select which treatment for OSA they
preferred.
Statistical Analysis
The data were analyzed with the statistical software
SigmaStat for Windows, version 2.0. A descriptive analysis
was used to define the study population. The results are
expressed as the means ¡ standard deviation, medians
(interquartile range) or percentages, as appropriate. The
Student’s t test for independent samples and an ANOVA
were used to compare the quantitative variables when
appropriate. The x2 test was used for the qualitative
variables. The potential explanatory variables used as
independent variables consisted of demographic and
clinical parameters. A p-value,0.05 was considered to be
significant.
RESULTS
During a one-year period, we invited 19 patients with
acromegaly to participate in this study. Seven patients were
excluded after diagnostic polysomnography due to an
AHI,15 events/h. Therefore, the total study sample
comprised 12 patients with moderate to severe OSA. All
of the patients had confirmed acromegaly (growth hormone
(GH): 1.32¡0.9 ng/l; insulin–like growth factor 1 (IGF1):
337¡180 ng/l) and were receiving octreotide. The demo-
graphic and clinical characteristics of the population
studied, including medications, are described in Table 1.
The body mass index (BMI) values of the patients did not
change during the intervention period (33.4¡4.8 Kg/m2
and 33.05¡4.9 Kg/m2 at the end of CPAP and NDS
treatment, respectively (p= 0.94)).
The sleep parameters at baseline, during CPAP titration
and with the use of NDSs are presented in Table 2. As
expected, the administration of CPAP virtually abolished
OSA. In contrast, the NDSs did not significantly alter OSA
severity. The mean CPAP pressure was 10.1¡1.1 cm H2O,
and median use of the CPAP was 6.6¡1.6 h per night. The
patients used the NDSs 98% of the nights studied. The
subjective parameters at the time of study entry and
following the use of CPAP and NDSs are presented in
Table 3. The reported satisfaction with the use of CPAP
and NDSs is shown in Table 4. The benefits of CPAP,
as perceived by the patient and measured by the ESS,
included improved sleep, less snoring, and a decrease
in sleepiness. The disadvantages of CPAP were mainly
related to the use of the mask and included the need to
adjust the mask to prevent air leakage and the discomfort
of using the mask, particularly related to the headgear. The
advantages of the NDSs included their perceived practi-
cality and comfort. At the end of the study, 10 patients
considered CPAP and two patients considered NDSs to be
the more effective treatment.
Table 1 - The demographic and clinical characteristics of
the patients.
(n =12) Mean¡SD
Age, ys 52¡8
Male/Female 8/4
Body mass index, Kg/m2 33.5¡4.6
Caucasians/Mulatto/Black, n 5/4/3
Abdominal circumference, cm 102¡8
Neck circumference, cm 42¡3
Hypertension, n (%) 9 (75)
Diabetes, n (%) 4 (33)
Diuretics, n (%) 5 (42)
b–Blockers, n (%) 3 (25)
ACE inhibitors, n (%) 5 (42)
Calcium blockers, n (%) 3 (25)
ARBs, n (%) 4 (33)
Antiplatelet, n (%) 3 (25)
Oral hypoglycemic, n (%) 6 (50)
Antidepressants, n (%) 3 (25)
The values represent the numbers of patients (percentage) or the
mean¡SD.
Abbreviations: ACE: angiotensin–converting enzyme; ARBs: angiotensin
receptor blockers.
Table 2 - Sleep parameters of the participants at baseline,
on nasal dilator strips and on CPAP.
Sleep Parameter Baseline CPAP NDSs p value
TST (min) 409¡51 378¡78 394¡55 0.49
Sleep efficiency (%) 86¡8 80¡16 88¡7 0.49
Sleep latency (min) 11¡13 16¡16 13¡15 0.71
REM latency (min) 91¡52 141¡90 110¡45 0.18
Stage 1 (%) 6¡3 7¡5 6¡5 0.58
Stage 2 (%) 64¡9 68¡11 61¡11 0.26
Stage 3 (%) 11¡5 12¡6 9¡6 0.35
REM (%) 20¡7 17¡10 18¡6 0.63
Arousal /h 27¡9 17¡10* 27¡9 0.02
AHI (events/h) 38¡14 8¡6* 39¡15 ,0.01
Apnea index (events/h) 17¡14 3¡3* 23¡18 ,0.001
Hypopnea
index(events/h)
22¡12 5¡4* 16¡7{ ,0.001
Obstructive apnea, n 79¡79 6¡10* 110¡99 ,0.001
Central apnea, n 22¡42 14¡13 28¡59 0.82
SatO2min,% 79¡7 86¡6* 79¡6 ,0.001
Abbreviations: CPAP: continuous positive airway pressure; NDSs: Nasal
dilator strips; TST: total seep time; REM: rapid eyes movements; AHI:
apnea-hypopnea index; SatO2min: minimal oxygen saturation. * Different
from CPAP whit baseline and NDSs. { Different from NDSs with baseline.
Variables expressed as mean¡SD. Variables with skewed distribution are
present as median (interquartile range).
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DISCUSSION
This crossover study tested the efficacy of NDSs to be
used as a placebo by comparing the objective and subjective
effects of CPAP versus NDSs in patients with acromegaly
and moderate to severe OSA. In contrast to CPAP, the NDSs
showed no effect on several polysomnographic parameters,
including sleep structure, arousals, AHI, and minimal
oxygen saturation. Despite the absence of objective effects,
patients treated with NDSs reported significant improve-
ments in several subjective measurements, including sleep
quality, snoring intensity, and somnolence during the day.
The subjective improvement associated with the use of
NDSs was intermediate and significantly lower than the
beneficial effects resulting from CPAP. The subjective
comparison at the conclusion of the study showed that the
vast majority of the patients (10 out of 12) considered CPAP
therapy to be more effective than NDSs. The high level of
adherence for the NDSs and the subjective improvements in
sleep associated with their use support the concept that
NDSs are an attractive control intervention for use in
controlled clinical trials aimed at evaluating the effects of
CPAP in patients with moderate to severe OSA in regards
to objectively measured (physiological or biochemical)
outcomes.
CPAP is the gold standard treatment for OSA and,
although effective at relieving symptoms, its role in
reducing long-term morbidities, such as cardiovascular
disease, requires further evaluation in trials that also include
proper control interventions. Because of its physical nature,
an ‘‘ideal placebo’’ for CPAP likely does not exist. In this
context, several alternatives, including pills, oral appliances,
and conservative treatment, have been used in RCTs
evaluating the effects of CPAP on different outcomes
(5,6,18,19). However, there has been little research that has
specifically evaluated the effectiveness of placebo candi-
dates. Several studies have argued that sham CPAP is an
appropriate control for CPAP, although sham CPAP may
serve as a poor placebo due to its negative effects on sleep
quality combined with the patients’ ability to identify the
sham treatment and secondary disappointment about being
placed in an untreated control group. In contrast, NDSs are
generally accepted by patients, many of whom perceive
benefits and thus may be motivated to continue with long-
term studies.
We reasoned that an ideal placebo should, similarly to
CPAP, be used every night but not adversely influence sleep
quality. Sleep apnea efficacy trials are typically designed to
Table 3 - PSQI component scores and global score of the
participants baseline, nasal dilator strips and CPAP.
Baseline CPAP NDSs p value
EES, score (0-24) 12¡6 5¡5* 9¡7 0.016
Global PSQI score 12¡3 4¡2* 6¡5 { ,0.001
PSQI .4, n (%) 12 (100 ) 5 (41)* 6 (50) 0.006
Subjective sleep
quality
2 (1.5–2.5) 1 (0–1)* 1 (1–1.5) { ,0.001
Sleep latency 2 (1.5–3) 0 (0–1)* 0.5 (0–1.5) { ,0.001
Sleep duration 3 (2–3) 1 (0–1.5)* 1 (0–1.5) { ,0.001
Sleep efficiency 3 (1.5–3) 0 (0–1)* 0.5 (0–1.5) 0.003
Sleep disturbances 2 (1.5–2) 1 (1–1)* 1 (1–2) 0.009
Use of sleep
medications
0 (0–0) 0 (0–0) 0 (0–0) 0.99
Daytime dysfunction 2 (2–2) 0 (0–1)* 1 (0–1) { ,0.001
Abbreviations: CPAP: continuous positive airway pressure; NDSs: Nasal
dilator strips; EES: Epworth Sleepiness Scale; PSQI: Pittsburgh Sleep
Quality Index.
Variables expressed as mean ¡ SD .Variables with a skewed distribution
are presented as medians (interquartile range). *For the comparisons
between CPAP with baseline; {For the comparisons between NDSs with
baseline.
Table 4 - Satisfaction treatment questionnaire of the participants with nasal dilator strips and CPAP.
Using the treatment over the last 3 months CPAP NDSs p value
How was your sleep? Much worse 0 0 NS
Worse 0 0
Equal 1 2
Better 4 5
Much better 7 6
How you felt upon waking? Much worse 0 0 NS
Worse 0 2
Equal 1 2
Better 5 6
Much better 6 2
You had some trouble falling asleep? Little difficult 1 1 NS
No difficult 2 2
Much difficult 9 9
How pleased was with the treatment? Very discontented 0 1 NS
discontented 0 1
Equal 1 1
Satisfied 4 3
Very satisfied 7 6
Did the treatment helped in your daily activities? No 0 2 NS
Yes 12 10
Rate the treatment (0–10)
0 = no effect
10 = maximal effect
9¡1 7¡3 0.01
Rate both treatments at the end of study (0 – 10)
0 = no effect
10 = maximal effect
9¡1 5¡3 0.007
Abbreviations: CPAP: continuous positive airway pressure; NDSs: Nasal dilator strips. Variable with normal distribution is express as mean ¡ SD.
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compare an active intervention, such as CPAP, with an
inactive treatment. Thus, the use of NDSs as a ‘‘placebo’’
assumes that NDSs do not positively (or negatively)
influence study outcomes. The effects of NDS are based
on the assumption that nasal resistance may play a pivotal
role in the genesis of OSA. Several studies have evaluated
the effects of different strategies to decrease nasal resistance
on OSA severity, and there have been controversial results
(20). The beneficial effects of NDSs on perceived snoring
and obstructed breathing are likely due to an active effect
resulting from the increased cross–sectional area of the nasal
cavity and the consequently reduced nasal airway resistance
(21). The efficacy of NDSs, however, remains controversial.
Although several studies have demonstrated beneficial
effects of NDSs on snoring (22-24), sleep maintenance
insomnia associated with sleep-disordered breathing (25),
and AHI (21,26,27), others have not supported these
findings (28,29). In our study, NDSs had no significant
effect on the AHI and caused a small but significant
decrease in the hypopnea index (Table 2). It is possible that
NDSs may have a somewhat greater effect in patient groups
besides this OSA–acromegaly patient sample. For example,
the study by Redline et al. (7) reported that NDSs had a
small beneficial effect on AHI in a subgroup of mildly
affected OSA patients with sinus disease. It is likely that,
among patients with moderate to severe OSA, neither the
site of obstruction during apnea nor the site of generation
during snoring is in the nose, and rather this location may
be in the oropharynx or hypopharynx at the level of the soft
palate or the velopharyngeal level (22). NDSs are therefore
an attractive placebo because they offer high patient
acceptability and a potential for minimal improvement in
the AHI, although the level of improvement in OSA is much
less than what can be achieved with CPAP.
The previously reported effects of sham CPAP (30),
conservative treatment (5), and oral placebos (6) on
subjective parameters have been extremely variable. For
instance, Jenkinson et al. (30) found a 29% improvement in
ESS associated with sham CPAP, whereas Engleman et al.
(6) found no effect of oral placebos on ESS. In contrast to
the overall lack of changes in objective measurements
observed in our study, patients given NDSs reported
significant improvements in several subjective measure-
ments, including quality of sleep, perceived snoring, and
symptoms of excessive daytime somnolence, as evaluated
by the ESS. Compared to the baseline values, the ESS score
decreased by 25% during NDS treatment, which is in line
with previously reported studies that also reported
positive effects of NDSs on ESS as high as 66% (21-
24,31). We also evaluated sleep quality by PSQI, and
whereas CPAP improved six out of seven PSQI items,
NDSs improved four of these items.
Our study had several limitations. First, we studied
patients with underlying acromegaly and OSA. Although
unlikely, it is possible that NDSs are more effective for
patients with OSA but without acromegaly. Second, the
number of patients studied in this report was relatively
small. However, the crossover nature of our study increased
its statistical power and allowed us to evaluate differences
between the CPAP and NDS arms not only for the objective
parameters but also for the subjective parameters.
Moreover, the study design enabled the comparison of the
strengths and limitations of each treatment according to the
patients’ perspectives. Finally, the long-term acceptability
and use of this type of placebo requires further study.
In conclusion, this study demonstrated that NDSs did not
appreciably affect objective measurements of sleep/OSA
but were associated with modest improvements in sub-
jective responses. Thus, NDSs may be an effective control
intervention for trials aimed at evaluating the objective
effects of CPAP in patients with OSA. The present study,
however, evaluated patients with acromegaly, and it is
possible that small beneficial effects may occur in other
groups, such as patients with mild OSA and nasal
obstruction. In those cases, the estimated differential effect
of CPAP may be modestly underestimated.
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